Pliant Therapeutics, Inc.(NASDAQ : PLRX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||1.32%||697.33||2.6%||$644.85m|
|GILD||Gilead Sciences, Inc.||-1.43%||62.86||1.0%||$494.49m|
|VRTX||Vertex Pharmaceuticals, Inc.||-1.01%||283.45||1.9%||$355.83m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-5.81%||4.05||0.7%||$283.11m|
|SAVA||Cassava Sciences, Inc.||-18.00%||41.87||0.0%||$173.71m|
|NRBO||NeuroBo Pharmaceuticals, Inc.||-6.44%||15.54||0.0%||$89.03m|
|BMRN||BioMarin Pharmaceutical, Inc.||-0.09%||84.84||4.2%||$76.07m|
|EXAS||EXACT Sciences Corp.||-2.74%||33.41||17.6%||$71.49m|
|CRSP||CRISPR Therapeutics AG||-2.68%||63.16||0.6%||$69.53m|
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ÃŸ1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.